This workshop, sponsored by Dawson James Securities, set out to create the highest-quality, full service investment firm specializing in the complex and fast-moving healthcare, biotechnology, technology and clean-tech sectors.

Whether you’re an institutional investor seeking expert guidance, a corporation requiring timely financial transactions or an individual investor needing superior service, Dawson James Securities, Inc. aims to deliver.

Learn more about Dawson James Securities

Tuesday, January 11th, 2011

Session 1 – Diagnostics & Personalized Medicine: Advances in molecular biology now make it possible to detect diseases sooner, allowing physicians to advise patients on optimal therapies. This panel explores the changing world of diagnostics, bringing together executives, experienced venture capitalists, and a physician. Together they will explore the product areas and business models that have made diagnostics a hot area for investors today. Along the way, panelists will discuss new technologies of interest to consolidators and address the challenges start-ups face in commercializing these game-changing products.

Panelists:

Session 2 – Neurology: Technological advances continue to give hope that new medical devices will improve the quality of life for people with neurological conditions such as epilepsy or Parkinsons’ Disease. There is also hope that these advances will stimulate better recovery for patients with neurological damage from traumatic events ranging from ischemic stroke to spinal cord injury. This panel, comprised of leading strategic/venture investors and industry veterans, will explore the most appealing therapeutic areas and technologies for investment in 2011. Panelists will discuss what it takes for a neurology-related company to succeed in today’s challenging economic and regulatory climate.

Panelists:
Denise Barbut, MD, Founder Benechill
Frank Fischer, President, Neuropace, Inc.
Mike Henson, General Partner, Medfocus Fund
Jeff Erb, Director Business Development, Medtronic

Session 3 – Urology and Womens Care: Urology and Women’s health have been areas of substantial M&A activity during the last 10 years as the major medtech consolidators have been busy building separate business units to address these medical needs. This panel includes representatives from several large medtech acquirers, as well as venture and private equity firms with major investments in this field. The panelists will explore exciting new products under development and the issues facing this dynamic market.

Panelists:
Jessica Grossman MD, Ethicon
Jan Garfinkle, Managing Partner, Arboretum Ventures
Ben Daverman, Partner, GTCR Golder Rauner
David Amerson, Global Vice President Coloplast Surgical Urology
Don Haut, Senior Vice President, Smith & Nephew

Wednesday, January 12th, 2011

Session 1 – Cardiology: Advances in structural heart repair/replacement, cardiac rhythm management, interventional techniques, cell replacement and regeneration therapies continue to refine one of the most successful areas of modern medicine: cardiac care. This panel of highly experienced medical and business professionals will describe what important products are on the horizon, and how these products will fare in a post healthcare – reform world.

Panelists:
Frank Litvack, Former President, Conor
Tao Forcht Dagi, MD, Partner, HLM Ventures
David Milne, Partner, SV LifeSciences
Michael Buck, Director Business Development, Abbott Ventures

Session 2 – Orthopedics: The orthopedic market include joint reconstruction, spine, trauma fixation, arthroscopy and biologics. Growth in each of these sectors is being driven by an aging US population. Today there are a large number of very innovative solutions in development which should offer the large orthopedic companies an opportunity to grow rapidly during the coming years. Join our panel of experts to explore the products in development and the interest and needs of the potential acquirers.

Panelists:
Bryan Hughes, Director, P & M Corporate Finance
Nancy Lynch, MD
John Barrett, CEO, CoAlign Surgical
Richard Ferrari, Partner, DeNovo Ventures
Karen Talmadge, Vice President Medtronic Inc.

Session 3 – Oncology: Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer. These advanced products include advanced cancer screening and imaging technologies, infusion of therapeutic materials directly into a tumor’s blood vessel, radiotherapy to treat solid tumors throughout the body more accurately and less invasively, as well as stem cell and antibody treatments to fight malignancies. This panel will discuss new products in development, their impact on patient care and the interest of medtech consolidators in these advanced therapies.

Panelists:
Scott Schalk, Managing Director, Dawson James
Daniel Kraft, MD
Euan Thompson, CEO, Accuray
Norm Weldon, Investor
Tom Umbel, Vice President, Hologic

Information:
Monday January 10th 2011
1:00 pm – 5:30 pm
Sir Francis Drake Hotel.
San Francisco

Advisory Board & Panelist:

Ames Gross, President, Pacific Bridge Medical
Caleb DesRosiers, Principal, Hillco Health
William McCluskey, CEO, Brean Murray Carret
William Ren, Managing Partner, MOY Shanghai
Chloe Liu, PhD, Managing Partner, Modular R&D
James Jiayuan Tong, MD PhD, CFO
Tianyin Pharmaceuticals
Judy Zakreski, VP US Operations, Chindex
Scott Lopez, SVP, Discovery Medical Investments
Robert Sun, President and CEO
Discovery Medical Investments
James Huang, Vivo Ventures
Dr. Yanhui (Michael) Ma, Chairman,
SinoMed Inc, Sinocare Inc.
PO CHI WU, Ph.D., 
Managing Director, Alameda Capital
Ned Brown, Senior Advisor, Health Evolution Partners
Kitty Wu, Co-founder & Partner, Ignatius Transaction Partners
Tony Zhang, Ph.D,Vice President, Global External R&D, Asia Eli Lilly & Company
Alex Suh, Managing Director, California Technology Ventures

Benjamin Chen, Co-founder & Partner, Ignatius Transaction Partners
Dr. Xiaoyi Li, CEO, Lee’s Pharmaceutical
Brett Johnson, CEO, OneMedPlace

$450 conference fee includes full conference transcript, program materials and database access.

Includes:
1. Audio recording of session. (formats for ipod and blackberry)
2. Executive Summary
3. Bibilography of Resources
4. Database Access

Each session module can be purchased separately.

Registrants do not need to attend to receive program materials and database access. Materials will be available electronically.

All registrants gain access to the OMP Global Database of companies and resources.

Additional database for purchase at discount rate:

China CRO 2010: the Authoritative Directory to Contract Research Organizations in China
OneMedForum attendees receive 10% discount on the full site access click here.

This workshop sponsored by Ronald Trahan Associates, Inc.

Serving the PR and IR needs of big and small Life Science companies, both public and private, since 1992.

Learn more about Ronald Trahan Associates Inc.